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Abstract. Background:Most studies evaluating extragenital testing performance for Chlamydia trachomatis (CT) and
Neisseria gonorrhoeae (NG) detection by the Xpert® CT/NG show high per cent agreement with comparison assays;
however, the precision around positive per cent agreement is low and thus the values that have been reported are not highly
informative. Therefore, a systematic review was conducted and data from five studies were combined to better assess
positive per cent agreement.Methods: The literature indexed on PubMed.gov was searched. Included studies were those
that were an evaluation of the Xpert CT/NG assay with rectal and/or pharyngeal specimen types compared with another
nucleic acid amplification test (NAAT), the Aptima transcription mediated amplification assay. A full Bayesian method
was used for bivariate fixed-effect meta-analysis of positive and negative per cent agreement and pooled estimates (and
95% confidence intervals (CI)) were presented for each. Results: The pooled positive and negative per cent agreement for
detection of CT in rectal specimens was 89.72% (95% CI: 84.97%, 93.64%) and 99.23% (95% CI: 98.74%, 99.60%), and
in pharyngeal specimens, they were 89.96% (95% CI: 66.38%, 99.72%) and 99.62% (95% CI: 98.95%, 99.95%)
respectively. For NG detection in rectal specimens, the pooled positive and negative per cent agreement was 92.75% (95%
CI: 87.91%, 96.46%) and 99.75% (95% CI: 99.46%, 99.93%), and in pharyngeal specimens, they were 92.51% (95% CI:
85.84%, 97.18%) and 98.56% (95% CI: 97.69%, 99.23%) respectively. Conclusions: It was found that the Xpert CT/NG
assay performed similarly to the Aptima transcription mediated amplification assay for the detection of CT and NG in
extragenital specimens. The Xpert assay has the benefit of providing faster results at the point-of-care, thus reducing the
turnaround time for results, potentially enabling same-day treatment.
Additional keywords: diagnosis, nucleic acid amplification test, pharyngeal, rectal.
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Introduction
Sexually transmissible infections (STIs) of Chlamydia
trachomatis (CT) and Neisseria gonorrhoeae (NG) continue
to place an immense health burden on men and women
worldwide. Both CT and NG infections are common STIs
accounting for 209 million cases globally each year.1 In the
USA alone, over 2 million chlamydial and gonoccocal
infections were reported to the USA Centers for Disease
Control and Prevention (CDC) in 2016, making those the
most common notifiable diseases in the USA.2
Routine screening, timely treatment and partner treatment
are mainstays of STI control programs. However, both
urogenital and extragenital CT and NG infections are
frequently asymptomatic3 and therefore go undetected and
untreated if screening tests are not performed. In the absence
of appropriate screening, extragenital sites may be important
reservoirs for CT and NG in a population, and can serve to
perpetuate the spread of these infections. Among men who have
sex with men, 65–77% of extragenital NG infections and
75–85% of extragenital CT infections are detected in the
absence of urethral infection, warranting routine screening at
extragenital sites in addition to urethral screening.4–6 Among
women, 14–44% of CT and NG infections may be missed
without extragenital screening.7–10
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Studies have shown that nucleic acid amplification
tests (NAATs) perform better than other tests available (e.g.
culture) for CT and NG detection.11–14 The CDC currently
recommends NAATs for the detection of CT and NG from
all anatomic sites.15 The Xpert® CT/NG assay (Cepheid,
Sunnyvale, CA, USA) is a NAAT with sample-to-result
instrumentation (on the GeneXpert® system) that can be
used in laboratories or at the point-of-care. Similar to other
STI NAAT assays, the Xpert CT/NG is Food and Drug
Administration (FDA) cleared for use with urogenital
specimens,16–18 and has recently been approved for use with
extragenital specimens.19
The Xpert CT/NG assay results are obtained in less than
90 min and are displayed on a computer system connected to the
test instrument via a data cable. The assay contains internal
quality control mechanisms including: a sample processing
control; a sample adequacy control; and a probe check
control, all of which are included in the Xpert CT/NG assay
cartridge. The sample processing control spikes DNA from the
non-pathogen, Bacillus globigii, which is then co-extracted and
co-amplified with the sample nucleic acid. Detection of this
control DNA verifies that binding and elution of target
DNA have occurred. The sample adequacy control reagents
detect the presence of the single-copy human gene encoding
hydroxymethylbilane synthase to monitor whether the sample
contains human DNA. Thus, a negative sample adequacy
control indicates that inadequate numbers of human cells
were present in the sample due to an inadequately collected
specimen, sample degradation or insufficient mixing. The probe
check control verifies reagent rehydration, polymerase chain
reaction tube filling in the cartridge, probe integrity and dye
stability.
Most studies evaluating extragenital testing performance for
CT and NG detection by the Xpert CT/NG show high per cent
agreement with comparison assays; however, because of the
limited sample sizes of CT-and NG-positive cases, the precision
around the positive per cent agreement is low.20–24 Therefore,
we aimed to combine data from all published studies of the
performance of extragenital testing with Xpert CT/NG to better
assess positive per cent agreement.
Methods
We searched the literature indexed on PubMed.gov (https://
www.ncbi.nlm.nih.gov/pubmed/) related to Xpert CT/NG
extragenital testing evaluations. We used the following
search terms: (Xpert OR GeneXpert OR Cepheid) AND
(extragenital OR rectal OR pharyngeal OR throat) AND
(chlamydia OR gonorrh*) (last search: 1 January 2018).
There were no language restrictions; however, only English
articles returned in our search. References within articles were
reviewed to identify additional relevant studies. Titles, abstracts
and full texts were reviewed for all articles, and a study was
included if it met the inclusion criteria of being an evaluation of
the Xpert CT/NG assay with rectal and/or pharyngeal specimen
types compared with another NAAT platform. C. C. Bristow
identified and selected articles. A review protocol was not
written.
Data were extracted from all included studies, including
author, publication year, sample size, sex of participants,
specimen types, reference tests and numbers of positive and
negative results on each assay into a data extraction spreadsheet.
We used SAS v9.4 (Cary, NC, USA) to perform all analyses.
We calculated per cent agreement, positive per cent agreement
and negative per cent agreement for each study and for
combined results. We calculated 95% confidence intervals
using the exact binomial method for each study individually.
We used a full Bayesian method for bivariate fixed-effect and
random-effects meta-analysis of positive per cent agreement
and negative per cent agreement with a SAS software procedure
(PROC MCMC)25 and present pooled estimates of each.
We considered a test of the deviance information criterion
(DIC) to assess the best model fit of the fixed-effect and
random-effects model. The fixed-effect model was
considered to be significantly better (substantial), if its DIC
was less than 10 greater than the DIC of the random-effects
model; that is, if (DICFIXED  DICRANDOM) <10.26 In addition,
we report the between-study heterogeneity of positive per cent
agreement and negative per cent agreement by univariate
Cochran Q-tests, using the free meta-analytic program, Meta-
DiSc, version 1.4.27 We also used the Meta-DiSc program to
calculate univariate I2-values for quantifying the between-study
heterogeneity. However, the Cochran Q-test and I2-values were
not used to determine best model fit.
Results
Our search yielded a total of eight publications,4,20–24,28,29
five20–24 of which met our inclusion criteria. We excluded
three studies because they were not evaluation studies.
Table 1 shows the included studies published between
2012 and 2017, with data from the USA and the UK. In
total, the studies included results from 1743 rectal specimens
and 986 pharyngeal specimens. All studies used the Aptima
transcription mediated amplification assay (Combo 2, Hologic,
San Diego, CA, USA) as the comparison test for the Xpert
CT/NG.
Figure 1a–d shows the calculated positive per cent
agreement and negative per cent agreement for each study
along with the pooled positive per cent agreement and the
pooled negative per cent agreement. The positive per cent
agreement in the studies ranged from 85.7% to 95.5% for
the detection of CT in rectal specimens and 88.4% to 100%
for the detection of NG in rectal specimens. The negative per
cent agreement ranged from 98.3% to 100% for CT in rectal
specimens and 99.4% to 100% for NG in rectal specimens.
For the detection of CT in pharyngeal specimens, the
positive per cent agreement ranged from 50% to 100% and
the negative per cent agreement ranged from 99.5% to 100%.
For the detection of NG in pharyngeal specimens, the positive
per cent agreement ranged from 77.8% to 97.3% and the
negative per cent agreement ranged from 97.5% to 100%.
We found that there was little heterogeneity (determined
using DIC of each random-effects and fixed-effect model)
between studies and therefore we report pooled estimates of
positive and negative per cent agreement from a fixed-effect
model. DIC values, Q-test results and I2 values are in the
Extragenital Xpert CT/NG meta-analysis Sexual Health 315
footnotes of Figure 1a–d. The pooled positive per cent
agreement and pooled negative per cent agreement for
detection of CT in rectal specimens was 89.72% (95% CI:
84.97%, 93.64%) and 99.23% (95% CI: 98.74%, 99.60%)
respectively. For NG detection in rectal specimens, the
pooled positive per cent agreement and pooled negative per
cent agreement was 92.75% (95% CI: 87.91%, 96.46%) and
99.75% (95% CI: 99.46%, 99.93%) respectively.
The pooled positive per cent agreement and the pooled
negative per cent agreement for detection of CT in pharyngeal
specimens was 89.96% (95% CI: 66.38%, 99.72%) and 99.62%
(95%CI: 98.95%, 99.95%) respectively. For the detection of NG
in pharyngeal specimens, the pooled positive per cent agreement
and pooled negative per cent agreement was 92.51% (95% CI:
85.84%, 97.18%) and 98.56% (95% CI: 97.69%, 99.23%)
respectively.
Discussion
CT and NG screening must be conducted using specimens from
the anatomic site of exposure if clinicians want to identify those
sites as infected. In addition, given most extragenital infections
in men and some in women occur in the absence of a urogenital
CT or NG infection, there is a need for reliable and accurate
screening tests for extragenital specimens. Currently, clinical
trials funded by the NIH (clinicaltrials.gov; NCT02870101)
have recently been completed to provide data and analyses to
support FDA applications for multiple NAAT diagnostic
platforms for the detection of pharyngeal and rectal CT and
NG.19
In this meta-analysis, we combined evidence from five
studies evaluating the Xpert CT/NG with extragenital
specimen types using Aptima transcription mediated
amplification assay, Combo 2, as the comparator. One study
used residual Aptima specimens and required a dilution of the
samples to overcome the incompatibility of the Aptima buffer
with the Xpert system; however, this study found a good
correlation between the two test systems.24 That reference
NAAT assay, the Aptima Combo 2, has demonstrated very
good sensitivity and specificity ranges for detection of NG and
CT in extragenital specimens across several studies of 71–100%
and 87.9–100% respectively.30 In all studies we included, there
was a lack of precision around estimates of positive per cent
agreement because of the small or moderate sample size of
positive specimens. Therefore, by combining evidence from all
five studies, we were able to achieve narrower confidence
intervals around positive per cent agreement. We chose to
use a fixed-effect model to generate the pooled estimates of
positive per cent agreement after identifying very little
heterogeneity between studies. Our findings suggest that the
Xpert CT/NG test was similar to another laboratory-based
NAAT for the detection of CT and NG in extragenital
specimens. We calculated per cent agreement for positive
and negative results separately and found that negative per
cent agreement was nearly 100% for both organisms at both
extragenital sites included in the study. We found that positive
per cent agreement was over 89% for both organisms at both
extragenital sites. Further studies may be needed to assess what
sensitivity value is acceptable in clinical practice in various
settings. Under ideal conditions, patient infection status would
be determined using an algorithm that includes multiple test
assays to ensure that the reference for a test evaluation was as
close to the true infection status of each participant as possible.
That would control for potential disease status misclassification
by the reference test(s). As a limitation, the positive per cent
agreement values in this study should be interpreted with
caution, as most studies did not include a tiebreaker or
confirmatory testing, therefore, the determination of infection
status of the anatomic site of each participant does not use an
optimal anatomic site infection status determination. However,
the clinical trial mentioned above uses multiple assays to
determine anatomic site infection status.
Our findings demonstrate that Xpert CT/NG assay results
were similar to a laboratory-based NAAT assay, Aptima
transcription mediated amplification assay, Combo 2, for the
detection of CT and NG in extragenital specimens. That Combo
2 NAAT has been laboratory verified for use with extragenital
specimens at multiple reference laboratories and thus was used
Table 1. Studies included in meta-analysis of Cepheid Xpert CT/NG assay extragenital testing
CT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; NA, not applicable
Author Year
Published
Xpert rectal
specimen type
Xpert pharyngeal
specimen type
Swab type/collection
kit for Xpert test
Comparison
test
Sex of and number
of participants’ specimens
Goldenberg et al.24 2012 Not stated NA Aptima unisex swabA Aptima Combo 2B 409 rectal (sex not stated)
Geiger et al.23 2016 Self-collected Self-collected Xpert CT/NG Swab
Collection Kit
Aptima Combo 2 144 pharyngeal, 141 rectal from
men who have sex with men
Dize et al.22 2018 Home self-collected NA Dry swab Aptima Combo 2 225C rectal from females,
223 rectal from males
Consentino et al.21 2017 Clinician collected Clinician collected Xpert CT/NG Swab
Collection Kit
Aptima Combo 2 224C from males and 175 from
females rectal and
pharyngeal
Bristow et al.20 2017 Self-collected Clinician collected Xpert CT/NG Swab
Collection Kit
Aptima Combo 2 393C rectal and 448 pharyngeal
specimens from males
AThe authors used remnant Aptima swabs for Xpert testing with the addition of a sample dilution step.
BAptima Combo 2-positive samples were confirmed with the Aptima CT or Aptima GC assay, which target alternate primers to those of the Aptima
Combo 2.
CSome specimen results excluded from analysis due to errors or invalid results.
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Author, year
Geiger 2016
Geiger 2016
Geiger 2016
Dize 2017
Bristow 2017
Bristow 2017
Cosentino 2017
Cosentino 2017
Cosentino 2017
Pooled (fixed effect)
Pos % agreementN
144 1 0 1 142 50.00 (1.26, 98.74)
100 (63.06, 100)
89.96 (66.38, 99.72) 99.62 (98.95, 99.95)
0 10 20 30 40
Positive percent agreement (CT pharyngeal)
50 60 70 80 90 100
0 10 20 30 40
Positive percent agreement (NG pharyngeal)
50 60 70 80 90 100
0 10 20 30 40
Positive percent agreement (CT rectal)
50 60 70 80 90 100
0 10 20 30 40
Positive percent agreement (NG rectal)
50 60 70 80 90 100
99.48 (98.14, 99.94)
100 (97.44,100)
394 8 2 0 384
TP FP FN TN Neg % agreement
Author, year Pos % agreement
97.30 (85.84, 99.93) 97.48 (95.27, 98.84)
100 (97.30, 100)
99.27 (97.89, 99.85)
98.56 (97.69, 99.23)
77.78 (39.99, 97.19)
91.18 (76.32, 98.14)
92.51 (85.84, 97.18)
86.05 (72.07, 94.70) 99.18 (97.62, 99.83)
100 (97.07, 100)
99.74 (98.54, 99.99)
98.26 (96.25, 99.36)
99.42 (97.92, 99.93)
99.23 (98.74, 99.60)
88.24 (63.56, 98.54)
95.45 (77.16, 99.88)
94.44 (84.61, 98.84)
85.71 (72.76, 94.06)
89.72 (84.97, 93.64)
Pooled (fixed effect)
Pooled (fixed effect)
Goldenberg 2012
N
394
144
448 31 4 3 410
7 0 2 135
36 9 1 348
TP FP FN TN Neg % agreement
Author, year Pos % agreementN
(a)
(b)
(c)
(d)
409 37 3 6 363
141 15 0 2 124
401 21 1 1 378
399 51 6 3 339
393
Geiger 2016
Dize 2017
Bristow 2017
Cosentino 2017
Pooled (fixed effect)
Goldenberg 2012 409 51
4
7
28 2 0
2 538
0 0
0 0
0 5 353 91.07 (80.38, 97.04) 100 (98.96, 100)
100 (97.34, 100)
100 (99.07, 100)
99.46 (98.07, 99.93)
99.43 (97.94, 99.93)
99.75 (99.46, 99.93)
100 (39.76, 100)
100 (59.04, 100)
100 (87.66, 100)
88.37 (74.92, 96.11)
92.75 (87.91, 96.46)
137
394
369
346
141
401
399
391
42 2 7 342
TP FP FN TN Neg % agreement
Author, year Pos % agreementN TP FP FN TN Neg % agreement
Fig. 1. (a) Xpert CT/NG Chlamydia trachomatis (CT) per cent agreement with comparison tests using rectal specimens. DICfixed–DICrandom
= 40.601–41.299. Positive per cent agreement Q-test 3.89, d.f. = 4, P = 0.421; negative per cent agreement Q-test 5.26, d.f. = 4, P = 0.262. Positive
per cent agreement I2 = 0%; negative per cent agreement I2 = 24.0%. (b) Xpert CT/NG Neisseria gonorrhoeae (NG) per cent agreement with comparison tests
using rectal specimens. DICfixed–DICrandom = 29.577–28.382. Positive per cent agreement Q-test 2.97, d.f. = 4, P = 0.563; negative per cent agreement Q-test
2.06, d.f. = 4, P = 0.724. Positive per cent agreement I2 = 0%; negative per cent agreement I2 = 0%. (c) Xpert CT/NG Chlamydia trachomatis per cent
agreement with comparison tests using pharyngeal specimens. DICfixed–DICrandom = 13.083–11.502. Positive per cent agreement Q-test 2.04, d.f. = 1,
P = 0.154; negative per cent agreement Q-test 0.07, d.f. = 1, P = 0.798. Positive per cent agreement I2 = 50.9%; negative per cent agreement I2 = 0%. (d) Xpert
CT/NGNeisseria gonorrhoeae per cent agreement with comparison tests using pharyngeal specimens. DICfixed–DICrandom = 29.216–25.657. Positive per cent
agreement Q-test 3.6, d.f. = 2, P = 0.165; negative per cent agreement Q-test 4.69, d.f. = 2, P = 0.096. Positive per cent agreement I2 = 44.4%; negative per cent
agreement I2 = 57.3%.
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as the reference test in the studies we identified. The Xpert
CT/NG assay has the benefit of providing faster results and can
be done at the point-of-care,17 thus reducing the turnaround time
for results,31–33 potentially enabling same-day treatment.
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